• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Anti-infectives
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
Archives
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
May 24, 2021

Director Retirement

Read More
April 29, 2021

FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2020

Read More
February 09, 2021

Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021

Read More
January 18, 2021

Appointment of Company Secretary

Read More
January 04, 2021

Lanstead Capital TR1

Read More
December 03, 2020

ImmuPharma to present at Biotech Showcase™ Digital 2021

Read More
November 30, 2020

Total Share Capital Notification

Read More
November 26, 2020

Grant of Share Options & PDMR dealing

Read More
November 24, 2020

Conversion of Convertible Security

Read More
November 23, 2020

Conversion of Convertible Security

Read More
November 20, 2020

FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients

Read More
November 19, 2020

Total Share Capital Notification

Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 17
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2021 | All rights reserved